Highly selective mass spectrometry.
Address your bioanalytical services needs across different modalities, including small molecules and peptides, large molecules, antibody-drug conjugates and others.
Small molecules
Bioanalysis begins with the careful selection of sample preparation technique and tuning the mass spectrometer for specific, selective and sensitive detection of your analyte of interest with multiple reaction monitoring (MRM) methodology. Your study design is optimized by factoring in:​
​
-
Sample complexity
-
Assay sensitivity
-
Assay robustness
​
​​The next step in the bioanalytical pathway is implementing a robust chromatographic method to separate the analyte of interest from endogenous constituents using gradient high-performance liquid chromatography (HPLC), retention characteristics and column selection. This allows highly selective mass spectrometry detection for the most optimal quantitative analysis of your compound.
Large molecules
The CRO industry has experienced an increase in the development of large molecule therapeutics. Work with our team of experts to learn about new opportunities created by advancements in large molecule quantification through the use of LC-MS/MS assays.
ADCs and mAbs
Explore a convenient approach for the quantitative analysis of monoclonal antibody (mAb)-based therapeutics with our innovative workflow. While the immunoaffinity capture reagent is highly specific for human mAbs with negligible cross-reactivity to immunoglobulins from common preclinical species, it is also versatile as it reacts with all human IgG subclasses. The combination of these immunoaffinity attributes with an optimized LC-MS/MS workflow results in a rapid plug-n-play bioanalytical solution for quantitative analysis of mAbs and antibody drug conjugates (ADCs) in matrices from preclinical species.
®
Other modalities
We offer the flexibility to implement parameters necessary for your study. This includes hitting the desired lower limit of quantitation (LLOQs) with limited sample volumes utilizing existing methods or developing and validating a custom method to support other modalities, including biomarkers.